Company news

Royalty Pharma plc news in 2025

Royalty Pharma plc's news releases, calls and decks from 2025, newest first.

View company

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

December 28, 2025

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

December 15, 2025

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

December 3, 2025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

December 3, 2025

Royalty Pharma to Present at Upcoming Investor Conferences

November 25, 2025

Royalty Pharma Reports Third Quarter 2025 Results

November 4, 2025

Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences

November 3, 2025

Royalty Pharma Declares Fourth Quarter 2025 Dividend

October 16, 2025

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 8, 2025

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

September 28, 2025

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

September 18, 2025

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

September 10, 2025

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market

September 9, 2025

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 3, 2025

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

September 1, 2025

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

September 1, 2025

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

September 1, 2025

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

August 24, 2025

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

August 24, 2025

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

August 12, 2025

Royalty Pharma Reports Second Quarter 2025 Results

August 5, 2025

Royalty Pharma Declares Third Quarter 2025 Dividend

July 17, 2025

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors

July 16, 2025

Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 15, 2025

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

June 23, 2025

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

Royalty Pharma Completes the Acquisition of Its External Manager

May 15, 2025

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

May 11, 2025

Royalty Pharma Reports First Quarter 2025 Results

May 7, 2025

Royalty Pharma Declares Second Quarter 2025 Dividend

April 20, 2025

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

April 16, 2025

Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

April 7, 2025

Royalty Pharma Announces Upcoming Investor Day

March 26, 2025

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

February 26, 2025

Royalty Pharma Announces R&D Funding Collaboration With Biogen

February 11, 2025

Royalty Pharma Reports Q4 and Full Year 2024 Results

February 10, 2025

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

January 28, 2025

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

January 27, 2025

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

January 9, 2025

Calls in 2025

Decks in 2025